Allarity Therapeutics Inc Cash Flow Conversion Efficiency
Allarity Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has a cash flow conversion efficiency ratio of -0.330x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.24 Million) by net assets ($9.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Allarity Therapeutics Inc (2015–2025)
Cash flow conversion efficiency of Allarity Therapeutics Inc from 2015 to 2025. This chart illustrates how Allarity Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALLR live share price for real-time trading data and today's change.
Allarity Therapeutics Inc Cash Flow Conversion Ratio Explained
Allarity Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Allarity Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allarity Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Allarity Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rocketdna Ltd
AU:RKT
|
-0.088x |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
-0.021x |
|
Scidev Ltd
AU:SDV
|
0.100x |
|
RPCG Public Company Limited
BK:RPC
|
0.061x |
|
Southern Fertilizer JSC
VN:SFG
|
0.325x |
|
Hands Corporation Ltd
KO:143210
|
0.308x |
|
Chiangmai Frozen Foods Public Company Limited
BK:CM
|
-0.032x |
|
Kyntra Bio, Inc.
NASDAQ:KYNB
|
0.490x |
Annual Cash Flow Conversion Efficiency for Allarity Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Allarity Therapeutics Inc from 2015 to 2025. Review free cash flow generation of Allarity Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.83 Million | $-14.82 Million | -1.508x | -2.64% |
| 2024-12-31 | $11.81 Million | $-17.35 Million | -1.469x | -131.71% |
| 2023-12-31 | $-2.75 Million | $-12.74 Million | 4.633x | +152.07% |
| 2022-12-31 | $1.89 Million | $-16.82 Million | -8.898x | -1010.55% |
| 2021-12-31 | $18.78 Million | $-15.05 Million | -0.801x | -196.70% |
| 2020-12-31 | $26.85 Million | $-7.25 Million | -0.270x | +44.18% |
| 2019-12-31 | $20.90 Million | $-10.11 Million | -0.484x | -218.50% |
| 2018-12-31 | $27.90 Million | $-4.24 Million | -0.152x | +95.55% |
| 2017-12-31 | $394.04K | $-1.34 Million | -3.413x | -346.16% |
| 2016-12-31 | $5.20 Million | $-3.98 Million | -0.765x | -85.86% |
| 2015-12-31 | $4.93 Million | $-2.03 Million | -0.412x | -- |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more